Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...
Hosted on MSN1h
European Equities Close Mostly Lower in Monday Trading; Entain Shares Drop After Australia Regulator LawsuitEuropean stock markets closed mostly lower in Monday trading as The Stoxx Europe was off 0.14%, Germany's DAX dropped 0.45%, the FTSE in London was down 0.46%, France's CAC declined 0.71%, while the ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Shortly after unveiling a $400 million upgrade at its campus in Hillerød, Denmark, Novo Nordisk is reinforcing its commitment ...
The latest update is out from Novo Nordisk ( (NVO) ).
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...
Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback